FibroBiologics, Inc. Operating Cash Flow
FibroBiologics, Inc. (FBLG) reported Operating Cash Flow of -$7.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-31
- FibroBiologics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.29M.
- FibroBiologics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$4.36M.
- FibroBiologics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.16M.
- FibroBiologics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$3.97M.
- FibroBiologics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$16.39M.
- FibroBiologics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$11.90M.
- FibroBiologics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$6.40M.
- FibroBiologics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$4.07M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | -$7.66M 10-Q · filed 2026-07-31 | -$10.82M derived: sum of 3 quarters · filed 2026-07-31 | -$14.79M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | -$4.36M 10-Q · filed 2026-04-30 | -$7.53M derived: sum of 2 quarters · filed 2026-04-30 | -$11.50M derived: sum of 3 quarters · filed 2026-04-30 | -$15.48M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | -$3.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$7.13M derived: sum of 2 quarters · filed 2026-02-24 | -$11.12M derived: sum of 3 quarters · filed 2026-07-31 | -$16.39M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$3.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-31 | -$7.96M derived: sum of 2 quarters · filed 2026-07-31 | -$13.23M 10-Q · filed 2025-10-31 | -$16.30M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | -$3.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | -$9.26M 10-Q · filed 2026-07-31 | -$12.33M derived: sum of 3 quarters · filed 2026-07-31 | -$14.94M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | -$5.28M 10-Q · filed 2026-04-30 | -$8.35M derived: sum of 2 quarters · filed 2026-04-30 | -$10.95M derived: sum of 3 quarters · filed 2026-04-30 | -$12.90M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$3.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$5.68M derived: sum of 2 quarters · filed 2026-02-24 | -$7.63M derived: sum of 3 quarters · filed 2026-02-24 | -$11.90M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$2.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-31 | -$4.55M derived: sum of 2 quarters · filed 2025-10-31 | -$8.83M 10-Q · filed 2025-10-31 | -$10.43M derived: sum of 4 quarters · filed 2025-10-31 |
| 2024-06-30 | -$1.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$6.22M 10-Q · filed 2025-07-31 | -$7.82M derived: sum of 3 quarters · filed 2025-07-31 | -$8.96M derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | -$4.28M 10-Q · filed 2025-05-14 | -$5.88M derived: sum of 2 quarters · filed 2025-05-14 | -$7.01M derived: sum of 3 quarters · filed 2025-05-14 | -$8.64M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$2.74M derived: sum of 2 quarters · filed 2025-03-31 | -$4.37M derived: sum of 3 quarters · filed 2025-03-31 | -$6.40M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$2.76M derived: sum of 2 quarters · filed 2024-11-12 | -$4.80M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$3.66M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | -$2.04M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | -$4.07M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 |